Results 151 to 160 of about 1,844,339 (310)
Random walks on weighted graphs, and applications to on-line algorithms [PDF]
, 1990 Don Coppersmith +3 more
openalex +1 more source
Timing and Predictive Value of Clinical Conditions Preceding Multiple Sclerosis in the UK Biobank
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives Multiple sclerosis (MS) patients often experience a higher incidence of clinical conditions before diagnosis, suggesting a prodromal phase. However, their predictive value and temporal trajectories remain underexplored. We investigated these aspects using the large UK Biobank's population‐based cohort, which provided clinical ...
Andrea Nova +5 more
wiley +1 more source
Estimating population size via line graph reconstruction. [PDF]
Algorithms Mol Biol, 2013 Halldórsson BV, Blokh D, Sharan R.
europepmc +1 more source
O( n log log n )-work parallel algorithms for straight-line grid embeddings of planar graphs [PDF]
, 1992 Martin Fürer +3 more
openalex +1 more source
A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester +4 more
wiley +1 more source
On Bivariegated Graphs and Line Graphs
, 2018 This note is on the structures of line graphs and 2-variegated graphs. We have given here solutions of some graph equations involving line graphs and 2-variegated graphs. In addition, a characterization of potentially 2-variegated line graphic degree sequences is given.
openaire +2 more sources
Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji +9 more
wiley +1 more source